Preparation of panaxadiol saponins component and pharmaceutical application for prevention and treatment of Parkinson disease

A technology of ginseng diol saponins and Parkinson's disease, applied in the field of medicine, can solve problems such as difficult medicinal value, increased incidence, involuntary movement, etc., to maintain or restore self-care ability and quality of life Effect

Active Publication Date: 2014-09-24
ZHEJIANG UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, dopa drugs have two major defects that cannot be overcome by themselves: one is the occurrence of motorfluctuation and abnormal, involuntary movements (abnormal involuntary movements) during treatment, which are defined as motor difficulties caused by levodopa ( Dyskinesia) or dyskinesia; with the prolongation of treatment time, the incidence rate continues to increase, about 50% after 5 years of treatment, and as high as 90% after 10 years of treatment
The second is that after 5 years of treatment, the curative effect gradually decreases, and finally it can be completely ineffective, which is caused by the neurotoxicity of levodopa.
This makes it difficult to realize the medicinal value of ginseng or American ginseng or their total saponins for effective treatment of central excitatory or inhibitory diseases and symptoms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation of panaxadiol saponins component and pharmaceutical application for prevention and treatment of Parkinson disease
  • Preparation of panaxadiol saponins component and pharmaceutical application for prevention and treatment of Parkinson disease
  • Preparation of panaxadiol saponins component and pharmaceutical application for prevention and treatment of Parkinson disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0058] Example 1 Preparation of Panaxadiol Saponin Fraction-A (PDSF-A) from Radix Ginseng

[0059] 1. Isolation and Purification of Panaxadiol Saponin Fraction-A (PDSF-A) :

[0060] Ginseng rhizome medicinal material (8000 grams, sample-A, five kinds of ginseng diol saponins Rb contained therein 1 , Rc, Rb 2 , Rb 3 and Rd content and their total content are shown in Table 5) after pulverizing into a coarse powder, use 50% ethanol aqueous solution to percolate and extract until the extract is colorless, combine the percolate to recover ethanol under reduced pressure and freeze-dry to obtain the extract (678.6 gram). The medicinal extract was dissolved in 3000 milliliters of 45% ethanol aqueous solution, and the sample liquid was separated by macroporous adsorption resin (Diaion HP-20, 6000 grams) column chromatography, and first eluted with 45% ethanol aqueous solution until the eluent had no obvious saponin reaction, and then eluted with 70% ethanol aqueous solution u...

Embodiment 2

[0083] Example 2 Preparation of Panaxadiol Saponin Component-B (PDSF-B) from American Ginseng Rhizome

[0084] With American ginseng rhizome medicinal material (7000 grams, sample-B, five kinds of ginseng diol saponins Rb contained therein 1 , Rc, Rb 2 , Rb 3 and the content of Rd and their total content are shown in Table 5, and its HPLC collection is shown in Figure 1-3 ), adopt the same method of embodiment one to prepare the ginseng diol saponin component - B (PDSF-B, 101.3 g). HPLC analysis shows: PDSF-B also contains ginsenoside Rb 1 , Rc, Rb 2 , Rb 3 and Rd five kinds of ginsenosides, the total content of these five kinds of saponins is 91.60%, of which ginsenoside Rb 1 The highest content, followed by Rb 3 , Rd, Rb 2 and Rc; and Rb in Panaxadiol Saponin Fraction-B 1 / Rc / Rb 2 / Rb 3 / Rd content ratio and Rb in American ginseng rhizome (sample-B) 1 / Rc / Rb 2 / Rb 3 The content ratio of / Rd is basically the same (Table 5).

Embodiment 3

[0085] Example 3 Preparation of Panaxadiol Saponin Component-C ( PDSF -C)

[0086] Purchased commodity ginseng rhizome total saponins (sample-C 1 , its total saponin content ≥ 80%) and American ginseng stem and leaf total saponin (sample-C 2 , its total saponin content ≥ 80%) show through HPLC analysis, five kinds of ginseng diol saponins contained in these two kinds of total ginsenoside products have their own characteristics respectively, namely: Sample-C 1 Both contain ginsenoside Rb 1 , Rc, Rb 2 , Rb 3 and Rd, but Rb 3 The content is very low (see attached diagram 2-1 and Table 5); Sample-C 2 Contains mainly Rb 3 and Rd, and Rb 1 , Rc and Rb 2 The content is very low (see attached Figure 2-2 and Table 5). This implementation comprehensively utilizes these two samples (sample-C 1 and sample-C 2 ) as this raw material to prepare the ginsengdiol saponin active component of the present invention, especially to obtain the total content of five kinds of ginseng...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of a ginsenoside component in the preparation of a drug for treating Parkinson's disease, the main components of which are ginsenosides Rb1, Rb2, Rb3, Rc and Rd. The medicine is composed of ginseng diol saponin component as an active ingredient alone or together with other medicines and a pharmaceutically acceptable carrier. Using raw materials such as ginseng rhizome medicinal materials, American ginseng rhizome medicinal materials, ginseng stem and leaf medicinal materials, American ginseng stem and leaf medicinal materials and their total extracts or total saponins, through macroporous adsorption resin and octadecylsilane bonded silica gel column chromatography combined Preparation by chromatographic separation and purification methods. The invention can improve the motor function of PD patients, supplement the balance between various nerve functions in the brain, and resist the degeneration of substantia nigra-striatum dopaminergic neurons and the neurotoxicity of levodopa drugs in PD patients. Treating neuropsychiatric disorders in PD patients and making levodopa effective in the long term. The structural formula of ginseng diol saponins is:.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to the preparation of a panaxadiol saponins active component (hereinafter referred to as panaxadiol saponins fraction, Panaxadiol Saponins Fraction, PDSF) and a kind of panaxadiol saponins fraction (PDSF) in the preparation and prevention of Parkinson's Application in Syndrome Drugs. More specifically, the comprehensive utilization of ginseng, American ginseng medicinal materials and their stems and leaves and their extracts or total saponins to prepare ginseng diol saponin components; and ginseng diol saponin components alone or with other substances including known therapeutic Pa The pharmaceutical preparation made of Kimson's syndrome drugs, especially levodopa drugs, is used in the treatment and prevention of Parkinson's disease and the synergistic and attenuating effects of levodopa drugs. Background technique [0002] Parkinson's disease is a complex disease characterized by motor dysfu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/704A61P25/16C07J17/00
Inventor 连晓媛张艳花张治针陈金龙
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap